Introduction {#s1}
============

Cannabis dependence (now cannabis use disorder), like all drug addictions, is a chronic, relapsing disorder marked by compulsive drug-taking despite negative consequences. Cannabis use has been associated with a range of adverse effects, including negative health outcomes ([@CIT0043]), acute and chronic mental health problems ([@CIT0055]), and psychosocial and cognitive impairments ([@CIT0018]). According to a recent review ([@CIT0007]), adult chronic cannabis users exhibit altered brain activity compared to healthy controls during cognitive tasks that involve sustained attention ([@CIT0014]; [@CIT0001]), working memory ([@CIT0040], [@CIT0041]), inhibitory control ([@CIT0035]), decision-making skills ([@CIT0071]), and psychomotor function ([@CIT0045]). These alterations in neural function and associated behaviors may contribute to continued use and relapse. The compulsion to use cannabis is often driven by stress ([@CIT0039]) and craving ([@CIT0025]), whereas cannabis use alleviates these negative feelings by reducing anxiety and craving ([@CIT0027]). When cannabis is smoked, the main psychoactive component, Δ9-tetrahydrocannabinol (THC; [@CIT0031]), is absorbed through the lungs and rapidly enters the bloodstream and crosses the blood-brain barrier within minutes ([@CIT0005]). Once in the brain, THC acts as a partial agonist at the endogenous cannabinoid 1 (CB1) receptor and interferes with the endogenous cannabinoid system ([@CIT0037]). CB1 receptors are located throughout the brain, but are mainly located in the hippocampus, amygdala, cerebellum, prefrontal cortex, and striatum ([@CIT0048]; [@CIT0020]; [@CIT0012]).

Preclinical studies have shown that THC exposure induces dose-dependent toxicity and structural changes in brain regions rich in CB1 receptors ([@CIT0037]); however, it remains unclear whether these preclinical findings are transferable to humans. Human structural magnetic resonance imaging (sMRI) studies have explored the effects of cannabis use on brain morphology by comparing gray matter differences between cannabis users and non-using controls, and provide insight into the potential effects of THC exposure on the brain (for reviews see [@CIT0050], [@CIT0051]; [@CIT0007]; [@CIT0060]). The most consistent findings have been smaller gray matter volume and lower gray matter density in the hippocampus/parahippocampus of cannabis users compared to non-using controls ([@CIT0052]; [@CIT0075]; [@CIT0004]; [@CIT0019]) with hippocampal gray matter volume in cannabis users inversely correlating with the total number of joints ([@CIT0004]) and cones smoked ([@CIT0075]). Other gray matter volume findings include smaller amygdalar gray matter volume ([@CIT0075]) and larger anterior cerebellar gray matter volume ([@CIT0017]) of cannabis users than controls; however, some studies report no structural alterations in cannabis users ([@CIT0010]; [@CIT0065]; [@CIT0075]). Furthermore, [@CIT0008] explored gray matter volume differences between occasional and regular cannabis users to better understand the long-term effects of cannabis use on brain structure and found that regular cannabis users exhibited smaller gray matter volume in the medial temporal cortex, temporal pole, parahippocampal gyrus, left insula, and the orbitofrontal cortex, and larger gray matter volume in areas of the cerebellum. The discrepancies across these studies have been attributed to several factors, such as heterogeneity in sample characteristics and methodological differences in data processing and analyses ([@CIT0050]), but could also be related to co-occurring use of cannabis and tobacco in the study populations.

Globally, cannabis and tobacco are commonly mixed together and smoked concurrently in a practice called mulling ([@CIT0022]). A recent study in Australia reported that nearly two-thirds of cannabis users combine cannabis and tobacco for smoking ([@CIT0006]). In the United States, co-occurring use is also prevalent among individuals over the age of 18, with 36% of current cigarette smokers reporting cannabis use during the past 30 days and 64% of current cannabis users reporting cigarette use during the past 30 days ([@CIT0066]). Although co-occurring use of cannabis and tobacco is prevalent, the extant literature examining the effects of cannabis and tobacco use on the brain focuses on their independent effects without sufficiently considering the effects of co-occurring use. Within the cigarette/tobacco smoking literature, sMRI studies indicate that smokers exhibit smaller gray matter volume and/or lower gray matter density than nonsmoking controls in the prefrontal, cingulate, insular, parietal, temporal, and occipital cortices, as well as in the thalamus and cerebellum ([@CIT0011]; [@CIT0030]; [@CIT0002]; [@CIT0074]; [@CIT0076], [@CIT0077]; [@CIT0049]; [@CIT0056]; [@CIT0029]; [@CIT0034]). Smokers have also been found to have larger gray matter volume/density than nonsmokers in several regions, including the insula ([@CIT0076]), putamen, and parahippocampus ([@CIT0029]). Despite similarities in their route of administration, apparent effects on gray matter, and prevalence of co-occurring use, previous research has not fully assessed and/or controlled for cannabis use within the cigarette smoking studies. Similarly, only two cannabis-related studies statistically controlled for cigarette use ([@CIT0041]; [@CIT0032]). Given the high rates of co-occurring cigarette and cannabis use and the potential effects of cannabis and cigarette smoking on brain structure, cigarette smoking and cannabis use should be considered in each of these disorders separately in order to ensure that gray matter differences are not incorrectly attributed to one drug or the other.

In the current study, we aimed to: (1) separate the effects of cigarette smoking from those of cannabis use and the effects of cannabis use from cigarette smoking on gray matter volume; (2) examine the effects of co-occurring cannabis and cigarette use on gray matter volume; (3) explore whether gray matter volume in cannabis users is associated with years of cannabis use; and (4) determine whether gray matter volume in cigarette smokers is associated with pack years, a measure of nicotine exposure. Unlike the majority of sMRI studies, which have primarily predefined regions of interest, we used a whole-brain voxel-wise approach and compared gray matter volumetric differences between cannabis-dependent individuals who have never smoked tobacco/cigarettes (Cs), cannabis-dependent individuals who smoke tobacco/cigarettes (CTs), nicotine-dependent, cannabis-naïve individuals (Ts), and healthy, non-using controls (HCs) using voxel-based morphometry (VBM). As mentioned above, the most consistent finding within the cannabis literature is smaller parahippocampal/hippocampal gray matter volume ([@CIT0052]; [@CIT0075]; [@CIT0004]; [@CIT0019]), so we hypothesized that Cs and CTs would exhibit lower gray matter volume in the parahippocampus/hippocampus than Ts and HCs. In a recent study, we found that nicotine-dependent cigarette smokers exhibited smaller gray matter volume in the thalamus and cerebellum, yet larger gray matter volume in the putamen and parahippocampus than controls ([@CIT0029]). We therefore hypothesized that Ts and CTs would show smaller gray matter volume in the thalamus and cerebellum and larger gray matter volume in the putamen compared to Cs and HCs.

Methods {#s2}
=======

Participants and Recruitment {#s3}
----------------------------

All study procedures adhered to the Declaration of Helsinki and were approved by the University of Pennsylvania Institutional Review Board. Physically healthy individuals were recruited via media advertisements and referrals who are: (1) cannabis-dependent and do NOT smoke tobacco (C); (2) cannabis-dependent and smoke tobacco (CT); (3) cannabis-naïve, nicotine-dependent, and smoke tobacco (T); and (4) non-using healthy controls (HC). After completing an initial telephone screen, individuals received a description of their respective study, provided written informed consent, and completed a screening visit (i.e. physical examination and psychological assessment) to ensure that they fulfilled all study criteria. Exclusion criteria included current DSM-IV Axis I diagnoses (other than cannabis or nicotine dependence), lifetime history of head injury with loss of consciousness for more than 3min, contraindications for magnetic resonance imaging, current treatment for cannabis dependence, clinically significant medical conditions, lifetime history of illicit drug use other than cannabis, and use of medication interacting with the central nervous system. Further details regarding the inclusion procedure are described in previous studies ([@CIT0029]; [@CIT0029]). Approximately 45 minutes prior to scan acquisition, CTs and Ts were provided the opportunity to smoke a cigarette to ensure that they were not experiencing nicotine withdrawal symptoms during data acquisition. Self-report of last cannabis use in Cs and CTs was obtained (mean time since last use = 0.69 days, standard deviation \[SD\] = 0.51). The final population selected for this study consists of 19 Cs (mean age = 28.0 years; SD = 6.9), 21 CTs (mean age = 30.9 years; SD = 8.8), 21 Ts (mean age = 34.3 years; SD = 9.4), and 21 HCs (mean age = 30.5 years; SD = 8.8). Demographic characteristics are shown in [Table 1](#T1){ref-type="table"}.

###### 

Demographic Characteristics

                                        C (n = 19)   CT (n = 21)   T (n = 21)   HC (n = 21)   *p*-values
  ------------------------------------- ------------ ------------- ------------ ------------- ------------
  Sex, n(%), male                       10 (53)      16 (76)       12 (57)      14 (67)       0.41
  Age                                   28 (7)       31 (9)        34 (9)       31 (9)        0.15^a^
  Years of education                    13 (2)       13 (1)        14 (1)       13 (1)        0.17
  Nicotine dependence (FTND)            \-           4.6 (1.3)     4.2 (1.6)    \-            0.51^b^
  Cigarettes per day                    \-           7.6 (6.7)     14.1 (4.4)   \-            0.001^b^
  Pack years                            \-           4.5 (4.9)     10.2 (8.2)   \-            0.009^b^
  Age of onset of weekly cannabis use   20 (6)       17 (12)       \-           \-            0.36^c^
  Cannabis use, years                   8 (6)        14 (9)        \-           \-            0.02^c^
  Cannabis use, past 30 days            27 (4)       25 (6)        \-           \-            0.11^c^
  Cannabis use, grams/week              14 (11)      20 (11)       \-           \-            0.07^c^

^a^ *p*-value for Kruskal-Wallis nonparametric test of difference between groups

^b^ *p*-values for comparison between CT and T groups

^c^ *p*-values for comparison between C and CT groups

Values are shown as means (standard deviation). C, cannabis-dependent individual who does not smoke tobacco; CT, cannabis-dependent individual who smokes tobacco; FTND, Fagerstrom Test of Nicotine Dependence; HC, healthy control; T, cannabis-naïve, nicotine-dependent individual who smokes tobacco.

For all participants, urine drug screens verified the absence of illicit drugs (e.g. cocaine, opiates, amphetamines) and the absence of nicotine and its major metabolite, cotinine, in C and HC groups. The cannabis groups completed urine and saliva tests during the screening process to confirm the regular use of cannabis consumption. The Timeline Follow-Back ([@CIT0063]) quantified cannabis, nicotine, alcohol, and opiate use during the past 30 days, and the Addiction Severity Index ([@CIT0053]) assessed lifetime cannabis, cocaine, amphetamine, heroin, opiate, barbiturate, hallucinogen, sedative, alcohol, and inhalant use. The Fagerstrom Test for Nicotine Dependence (FTND; [@CIT0024]) assessed severity of nicotine dependence among CTs and Ts.

Magnetic Resonance Acquisition {#s4}
------------------------------

Imaging data were acquired on a Siemens 3 Tesla Trio whole-body scanner (Erlangen) at the Hospital of the University of Pennsylvania using a product 8-channel head coil. High-resolution T1-weighted anatomical images were obtained using a 3D-magnetization prepared rapid acquisition gradient echo sequence (repetition time = 1620ms, echo time = 3ms, flip angle = 15°, 160 contiguous slices of 1.0mm).

Data Processing {#s5}
---------------

Data were preprocessed and analyzed using the Statistical Parametric Mapping (SPM8, Wellcome Department of Cognitive Neurology) VBM8 toolbox (<http://dbm.neuro.uni-jena.de/vbm>) implemented in MatlabR2013 (MathWorksInc.). Each subject's T1-weighted images were checked for structural abnormalities and reoriented to the anterior-posterior commissure line. Reoriented images were segmented into gray matter, white matter, and cerebral spinal fluid in native space using the New Segmentation algorithm. The resulting rigidly aligned and resliced gray matter tissue maps were imported into DARTEL (Diffeomorphic Anatomical Registration Using Exponentiated Lie Algebra), an advanced high-dimensional diffeomorphic registration algorithm shown to improve spatial precision ([@CIT0003]). Subsequently, a study-specific gray matter template was created from the imported maps of all participants. The final average gray matter template was generated after six iterations by averaging all of the aligned images. During successive iterations, flow fields for each participant's images were yielded to parameterized deformations by warping to the template. The warped gray matter maps were transformed into Montreal Neurological Institute space and were scaled by the Jacobian determinants of the deformations. Finally, the normalized modulated maps were smoothed with a Gaussian kernel of 8mm full width half maximum.

Data Analysis {#s6}
-------------

Demographics and questionnaire scores were examined for normality, and non-normal data (i.e. pack years, days of cannabis use) were log transformed. A Kruskal-Wallis nonparametric test examined group differences in age, and all other group differences were assessed using an analysis of variance. Voxel-based inferential statistics were performed on the smoothed modulated gray matter images using an analysis of covariance (ANCOVA) for investigating the main effect of group (*F*-test). Age and sex were included as covariates of no interest. Given that gray matter differences between adults with cannabis and tobacco co-use, adults who only use cannabis, and adults who are cannabis-naïve but smoke tobacco have never been reported, the data were analyzed using the voxel-wise threshold of *p* \< 0.001 with a family-wise error correction for multiple comparisons (*p* \< 0.05). To conduct post hoc pairwise comparisons and to explore associations between gray matter volume and measures of cannabis (e.g. years of cannabis use, age of cannabis use onset, grams of use per week, days of cannabis use in the past month) and tobacco use (e.g. years of cigarette use, age of cigarette use onset, cigarettes per day, pack years, and nicotine dependence), gray matter volume within each significant cluster was extracted for each participant using the MarsBaR tool in SPM (<http://marsbar.sourceforge.net/>) and exported to IBM SPSS Statistics 19.0. In SPSS, a series of ANCOVAs tested for main effect of group and confirmed SPM findings. Subsequent post hoc pairwise comparisons were conducted (e.g. Cs vs. CTs; Cs vs. Ts; Cs vs. HCs, etc.) to determine whether group differences were significant.

Results {#s7}
=======

Demographic Characteristics {#s8}
---------------------------

As shown in [Table 1](#T1){ref-type="table"}, groups did not differ in age, sex, or years of education. Comparisons between CT and T groups revealed that T individuals smoked more cigarettes per day and had greater pack years than CT individuals, but did not differ in nicotine dependence (FTND). Cannabis-dependent individuals (C vs CT groups) did not differ in age of cannabis use onset, cannabis use days (past 30 days), or amount of cannabis use (grams/week), but did differ in years of cannabis use.

VBM Analysis {#s9}
------------

Whole-brain analyses revealed significant differences in gray matter volume between groups in the left putamen, right precentral gyrus, left cerebellum, and thalamus ([Figure 1](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). Pairwise comparisons within these clusters showed that the C group, CT group, and T group had greater gray matter volume in the left putamen compared to HCs, and Cs had greater gray matter volume in the right precentral gyrus compared to HCs. HCs showed greater gray matter volume in the thalamus compared to Cs and CTs. HCs also had greater gray matter volume in the left cerebellum than the CT and T groups. Finally, among those who use cannabis (i.e. Cs and CTs), partial correlations examined potential associations between gray matter volume and measures of cannabis use with age, sex, and pack years as covariates. No significant correlations were observed.

###### 

Regional Gray Matter Volume Differences

  --------------------------------------------------------------------------------------------------------------------------------------------------
  **Brain region**   ***MNI coordinates* x y z**   ***F*-values**   **Cluster size (voxels**)   **Pairwise comparisons** ^**a**^         
  ------------------ ----------------------------- ---------------- --------------------------- ---------------------------------- ----- -----------
  L Putamen          -26                           -4               2                           17.84                              387   C \> HC\
                                                                                                                                         CT \> HC\
                                                                                                                                         T \> HC

  R Precentral       26                            -16              64                          11.97                              667   C \> HC

  L Cerebellum       -38                           -76              -44                         9.82                               750   HC \> CT\
                                                                                                                                         HC \> T

  Thalamus           2                             -16              6                           9.73                               392   HC \> C\
                                                                                                                                         HC \> CT
  --------------------------------------------------------------------------------------------------------------------------------------------------

Voxel-wise height threshold of *p* \< 0.001, *p* \< 0.05 famiy-wise error cluster-corrected. C, cannabis-dependent individual who does not smoke tobacco; CT, cannabis-dependent individual who smokes tobacco; HC, healthy control; L, left; MNI, Montreal Neurological Institute brain; R, right; T, cannabis-naïve, nicotine-dependent individual who smokes tobacco.

![Group differences in gray matter volume. Clusters of significant volume differences (*p* \< 0.001, famiy-wise error (FWE) cluster-corrected at *p* \< 0.05) are displayed on representative sagittal, coronal, and axial slices overlain on the standard Montreal Neurological Institute brain. Right side of the brain is depicted on the right side. C, cannabis-dependent individual who does not smoke tobacco; CT, cannabis-dependent individual who smokes tobacco; HC, healthy control; L, left; R, right; T, cannabis-naïve, nicotine-dependent individual who smokes tobacco.](ijnppy_pyv061_f0001){#F1}

Similar partial correlation analyses were conducted for CTs and Ts by exploring associations between gray matter volume and measures of tobacco cigarette use with age, sex, and years of cannabis use as covariates. No significant correlations were found between gray matter volume and measures of tobacco use.

Discussion {#s10}
==========

The current study provides evidence that cannabis and tobacco have differential effects on gray matter volume; however, co-occurring cannabis and tobacco use does not appear to have a distinct effect compared to only smoking cannabis or cigarettes. In general, our findings are largely consistent with research suggesting that long-term cannabis and tobacco smoking alters the brain structure in regions rich in cannabinoid 1 (CB1) receptors ([@CIT0064]) and nicotinic acetylcholine receptors ([@CIT0057]). Specifically, groups differed in gray matter volume in the left putamen, right precentral gyrus, thalamus, and left cerebellum. Compared to controls, Cs, CTs, and Ts exhibited larger gray matter volume in the left putamen, yet only Cs showed larger gray matter volume in the right precentral gyrus. Cannabis appeared to have a unique effect in the thalamus, with Cs and CTs having smaller gray matter volume than HCs, whereas nicotine appeared to have a unique effect within the left cerebellum, with CTs and Ts having smaller gray matter volume than HCs. Cannabis use and tobacco use measures did not correlate with gray matter volume in any of the above clusters.

Larger Gray Matter Volume in Cannabis- and Nicotine-Dependent Individuals {#s11}
-------------------------------------------------------------------------

Cs, CTs, and Ts had larger gray matter volume in the left putamen (dorsal striatum) than HCs. Striatal abnormalities are thought to underlie habitual, compulsive drug seeking and use despite negative consequences ([@CIT0023]; [@CIT0046]). Further, the striatum is an important part of the mesolimbic dopamine pathway, and as such, our findings suggest that the dopamine system may be a common mechanism for cannabis- and tobacco-related structural alterations. Similarly, previous studies have shown that methamphetamine-dependent individuals have greater gray matter volume within the putamen compared to controls ([@CIT0013]; [@CIT0042]; [@CIT0016]). Enlarged striatal volume has also been reported in other psychiatric disorders characterized by repetitive, compulsive behaviors, such as autism ([@CIT0038]) and obsessive-compulsive disorder ([@CIT0061]). Further, severity of compulsivity has been associated with increased striatal gray matter volume ([@CIT0059]). As such, the increased striatal gray matter volume observed in our cannabis- and nicotine-dependent groups may be associated with the long-term, compulsive use of cannabis and tobacco. It is important to note, however, that recent research suggests that greater putamen gray matter volume may be present before the onset of substance use and could influence the development of substance use disorders ([@CIT0021]). Thus, gray matter volume differences in the putamen could contribute to and/or result from substance use disorders.

We also found that Cs differed from HCs in right precentral gray matter volume, with Cs exhibiting larger gray matter volume than HCs. The precentral gyrus, also known as the primary motor cortex, has been principally identified with motor function ([@CIT0058]; [@CIT0026]) and appears to play a role in cannabis dependence. Specifically, our finding is consistent with a previous study indicating that compared to men who do not smoke cannabis, men who smoke cannabis have greater gray matter density within the precentral gyus ([@CIT0052]). THC has been found to impair psychomotor function ([@CIT0045]) and increase activation within brain areas involved in motor control and coordination, including the precentral gyrus ([@CIT0068]). This increase in brain metabolism during slower, inaccurate motor performance has been attributed to cannabis users having to "work harder" to complete a task ([@CIT0044]); however, other work suggests that cannabis users recruit motor and attention areas more extensively ([@CIT0069]). Accordingly, one possible explanation for the larger gray matter volume within the precentral gyrus could be due to neuroadaptations associated with the repeated increase of blood flow and brain metabolism within the region due to chronic THC exposure ([@CIT0036]; [@CIT0062]), as recent research suggests that brain blood flow and gray matter volume are systematically linked ([@CIT0067]). Future research is warranted given that only Cs, not CTs, exhibited this difference; however, at an uncorrected *p* \< 0.001 threshold, CTs also exhibited greater gray matter volume in the right precentral gyrus.

Smaller Gray Matter Volume in Cannabis- and Nicotine-Dependent Individuals {#s12}
--------------------------------------------------------------------------

We also found that Cs and CTs had smaller gray matter volume in the thalamus compared to HCs. Similar reductions in thalamic gray matter volume have been observed in individuals at high familial risk of psychosis who smoke cannabis ([@CIT0070]); however, reductions in thalamic gray matter volume were not reported in other studies among adults who smoke cannabis, which is surprising given that the thalamus has been identified as a structure involved in mediating responses to cue-driven behaviors, especially in the context of addiction ([@CIT0033]). At the famiy-wise error-corrected threshold, Ts did not exhibit smaller gray matter volume in the thalamus compared to HCs, which contradicts some studies ([@CIT0030]; [@CIT0049]) but not others ([@CIT0011]). Given that cigarette smoking behavior is complex and that various aspects of the behavior are modulated by both known ([@CIT0009]; [@CIT0028]; [@CIT0029]) and unknown factors, we speculate that differences in other characteristics (e.g. sex, genetics) are contributing to discrepancies across studies.

Unique Differences Between Cannabis- and Nicotine-Dependent Groups {#s13}
------------------------------------------------------------------

The left cerebellum was identified as a brain region wherein tobacco smokers (CTs and Ts) showed smaller gray matter volume than HCs. This finding is consistent with previous studies demonstrating cerebellar gray matter differences between cigarette smokers and healthy controls ([@CIT0074]; [@CIT0047]; [@CIT0029]). Preclinical research suggests that long-term nicotine exposure results in a significant loss of cerebellar Purkinje cells ([@CIT0015]), and as such, similar reductions could occur among human cigarette smokers and result in smaller cerebellar volume compared to HCs. It is important to note, however, that this interpretation is speculative and additional research on the effects of nicotine on the cerebellum is warranted.

Unlike two previous studies among cannabis-using adult ([@CIT0017]) and adolescent populations ([@CIT0054]), we did not find cerebellar volume differences between cannabis-dependent adults who do not smoke tobacco and healthy controls. Discrepancies may be attributable to differences in methodology and cannabis use histories. Specifically, the previous studies used *a priori* regions of interest approaches and examined populations who were not cannabis dependent and who reported less cannabis use. Further, the earlier studies did not control for cigarette smoking, and as such, the cerebellar findings could actually be due to nicotine exposure rather than cannabis use. As such, additional studies are needed to assess the effects of cannabis use (without concurrent tobacco smoking) on cerebellar brain structure.

Contrary to our hypotheses, we did not find differences in hippocampal gray matter volume among Cs and CTs. It is important to note that at an uncorrected *p* \< 0.001 threshold, Cs and CTs exhibited smaller gray matter volume, and as such, this null finding could be due to our conservative statistical approach, as CTs and Cs showed smaller hippocampal gray matter volume compared to HCs and Ts at a lower, more liberal statistical threshold.

Correlations Between Gray Matter Volume and Measures of Cannabis and Tobacco Use {#s14}
--------------------------------------------------------------------------------

We did not find significant correlations between cannabis and tobacco use measures and gray matter volume. Null findings may be related to our conservative statistical approach and focus on clusters showing significant differences. Thus, additional research is necessary.

Limitations {#s15}
-----------

This study has several important strengths and limitations. It is the first study to explore the differential effects of cannabis, tobacco, and concurrent cannabis and tobacco use among adults. The groups were well-matched on demographic characteristics, and by including Cs, CTs, Ts, and HCs, we examined the unique effects of each substance and their co-occurring use on adult gray matter. This cross-sectional study design prohibits our ability to dissociate causal effects of cannabis and tobacco smoking from predisposing biological factors. Our sample size also precludes us from examining how other factors, such as sex and genetic vulnerabilities, may influence these findings.

Conclusion {#s16}
----------

This VBM, sMRI study provides new information on the effects of cannabis, cigarettes, and co-occurring cannabis and cigarette smoking on brain structure. Cannabis, tobacco, and their co-occurring use had similar effects within several brain regions associated with motivation and reward, yet differed in unique ways in the cerebellum and thalamus. Although longitudinal studies are needed, this study extends previous studies that independently examine the effects of cannabis or tobacco use on brain structure by including an examination of co-occurring cannabis and tobacco use, exclusive use of one or the other.
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